[Federal Register Volume 62, Number 99 (Thursday, May 22, 1997)]
[Notices]
[Pages 28045-28048]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-13427]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Government-Owned Inventions; Availability for Licensing

AGENCY: Office of Technology Transfer, Centers for Disease Control and 
Prevention (CDC), Department of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

    The inventions named in this notice are owned by agencies of the 
United

[[Page 28046]]

States Government and are available for licensing in the United States 
(U.S.) in accordance with 35 U.S.C. 207 to achieve expeditious 
commercialization of results of federally funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for U.S. companies and may also be 
available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to Marjorie 
Hunter, Licensing Specialist at the Technology Transfer Office, Centers 
for Disease Control and Prevention (CDC), Mailstop E-67, 1600 Clifton 
Rd., Atlanta, GA 30333, telephone (404) 639-6271; facsimile (404) 639-
6266. A signed Confidential Disclosure Agreement will be required to 
receive copies of the patent applications.

Methods and Compositions for an Artificial Lung Organ Culture System

Quinn, F. D.; Birkness, K. A.
Filed 23 September 94
Serial No. 08/679,081 (Ref # E-14)

    Methods have been developed creating an artificial lung culture 
system, comprised of multiple human cell layers, for studying the 
passage of pathogens and chemical substances through the organ. The 
system is comprised of an endothelial cell layer and an alveolar 
epithelial cell layer oriented on either side of, and in direct contact 
with, an artificial microporous membrane. This stable culture system 
provides a more complex system for study than simple monolayers of 
human cells or animal models. The culture system is easily maintained 
without the use of antibiotics and is viable for longer periods of time 
than other models. (Portfolio: Human Organ, Tissue Culture, Liver.)

Infectious cDNA Clones for Dengue Virus: Strain 16881 and Live 
Attenuated Vaccine Derivative, Strain PDK-53

Kinney, R. M.; Gubler, D. J.; Trent, D. W.; Halstead, S. B.; Chang, J.; 
Butrapet, S.; Bhamarapravati, N.
Filed 7 June 95
Serial No. 08/483,292 (Ref # E-132-95/0)

    A quadravalent vaccine which evokes immunity against all four 
serotypes of dengue virus comprising DEN-2 PDK-53 infectious clone 
derivative, DEN-2/1, DEN-2/3, or DEN-2/4 viruses, and related methods 
of immunization are described in this invention. The invention also 
provides a method of cloning and sequencing a cDNA copy of an entire 
RNA genome of the PDK-53 vaccine derivative of dengue 2 virus, strain 
16681, which can be used to engineer new dengue vaccines as well as 
recombinant chimeric viruses. This invention provides a host cell with 
multiple constructs of protein encoded by several nucleotide sequences. 
(Portfolio: Vector-borne Infectious Diseases, Vaccine, Dengue, Chimeric 
Viruses.)

SecA Gene of Mycobacterium Tuberculosis and Related Methods and 
Compositions

Quinn, F. D.; Owens, M. H.; King, C. H.
Filed 22 February 95
Serial No. 08/394,646 (Ref # E-066-95/0)

    This invention includes an isolated nucleic acid encoding a SecA 
protein of Mycobacteria tuberculosis. This nucleic acid can be a native 
coding sequence for the SecA protein or any alternative coding sequence 
for the SecA protein of M. Tuberculosis. An isolated fragment of the 
secA gene that is specific for M. Tuberculosis is also provided. A 
purified SecA protein of M. Tuberculosis which comprises the sequence 
set forth in the Sequence Listing as SEQ ID NO: 2 is provided. 
Fragments of the M. Tuberculosis SecA protein, a purified mutant SecA 
protein of M. Tuberculosis, and a purified mutant M. Tuberculosis 
expressing the mutant SecA protein are provided in the invention.
    The invention provides methods of screening for putative M. 
Tuberculosis virulence factors translocated by the SecA protein. In one 
example of the method (the method comprises: inhibiting the 
translocation ATPase activity of the M. Tuberculosis SecA protein, and 
detecting the accumulation of precursor forms of proteins in the 
cytoplasm of the M. Tuberculosis cells) the accumulation of a precursor 
indicating the presence of a translocation ATPase activity of the M. 
Tuberculosis SecA protein can be inhibited by administering an amount 
of sodium azide to M. Tuberculosis cells or by mutating the secA gene 
so that it produces a non-lethal translocation ATPase deficient M. 
Tuberculosis mutant.

Treating HIV Infection by Inhibiting Bcl-2

Sandstrom, P. A.; Folks, T. M.
Filed 29 January 96
Serial No. 08/593,407 (Ref # E-102-
95/0)
    This invention provides a method of treating an HIV infection by 
inhibiting Bcl-2 expression or activity. This invention also provides a 
method of screening for a compound that inhibits HIV replication. This 
invention also provides a cell line transfected with a nucleic acid 
that encodes Bcl-2, wherein the cell line expresses bcl-2, and the cell 
line is infected with HIV. (Portfolio: HIV, AIDS, Viral Infection, 
Cellular Biology.)

Methods for Sensitive Detection of Reverse Transcriptase Activity

Heneine, W.; Folks, T. M.; Switzer, W. M.; Yamamoto, S.
Filed 27 January 95
Serial No. 08/379,851 (Ref # E-232-
93/0)

    This invention provides a method for detecting a retrovirus in a 
biological sample by identifying the presence of the enzyme reverse 
transcriptase (RT). This RT assay employs a PCR-based amplification 
system to detect a known cDNA product of the RT reaction. This 
invention is highly sensitive and specific and requires no knowledge of 
viral genomic sequence. Retroviruses that previously would have gone 
undetected may now be identified. (Portfolio: PCR, Reverse 
Transcriptase, Retrovirus, Diagnosis.)

Nucleotide Sequences of New Hantavirus--``Bayou Virus''

Nichol, S.; Morzunov, S.; Ksiazek, T.; Rollin, P.; Spiropoulou, C.
Filed 17 February 95
Serial No. 08/390,888 (Ref # E-183
-93/2)

    Nucleotide sequences of the M and S segments of the Louisiana virus 
genome have been identified. Included are several different methods of 
detecting the ``Bayou'' hantavirus and isolated nucleic acids specific 
for the ``Bayou'' hantavirus. Purified antigenic polypeptides and 
antibodies that specifically bind to the ``Bayou'' hantavirus or those 
polypeptides are provided. (Portfolio: Hantavirus, Bayou.)

Nucleic Acids of a Novel Hantavirus and Reagents for Detection and 
Prevention of Infection. The ``Sin Nombre'' Hantavirus

Rollin, P.; Elliott, L.; Ksiazek, T.; Nichol, S.
Filed 24 June 94
Serial No. 08/569,242 (Ref # E-183-
93/3)

    This invention describes a nucleotide sequence for a new 
hantavirus, referred to as ``Sin Nombre'' hantavirus, which is the 
causative agent of hantavirus pulmonary syndrome. A method of detection 
of the ``Sin Nombre'' hantavirus and an associated method of prevention 
of infection is provided. The

[[Page 28047]]

``Sin Nombre'' virus strain was previously known as the ``Muerto 
Canyon'' hantavirus. (Portfolio: Hantavirus, Diagnosis.)

The Black Creek Canal Strain of Hantavirus and Methods of Detection and 
Prevention of Infection Therefrom

Nichol, S. T.; Elliott, L.; Ksiazek, T. G.; Morzunov, S.; Ravkov, E.; 
Rollin, P. E.
Filed 17 February 95
Serial No. 08/390,361 (Ref # E-183-
93/4)

    The Black Creek Canal strain of hantavirus, which is responsible 
for a case of hantavirus Pulmonary Syndrome in Florida, is provided. 
The virus was isolated from a rodent and is genetically different at 
the nucleotide level from the Muerto Canyon virus. The invention also 
provides purified polypeptides encoded by the nucleic acids, purified 
antibodies that bind the hantavirus, and describes methods of detection 
and prevention. (Portfolio: Hantavirus, Vaccine, Black Creek Canal 
Strain.)

Method and Composition for Diagnosing Cat Scratch Disease and Bacillary 
Angiomatosis Caused by Rochalimaea Henselae (Now Referred to as 
Bartonella Henselae)

Regnery, R. L.; Anderson, B.E.
Patent Issued: 21 March 95
Patent No. 5,399,485 (Ref # E-048-92/0)

    This invention provides a method of diagnosing cat scratch disease 
and bacillary angiomatosis by detecting the presence of Bartonella 
henselae or an immunogenically specific determinant thereof in humans 
or animals. Also provided is a vaccine comprising an immunogenic amount 
of a nonpathogenic Bartonella henselae and a pharmaceutically 
acceptable carrier. (Portfolio: Vaccine, Cat Scratch Disease, 
Bartonella.)

Method for Detection of a New Marker Associated With Hepatitis Delta 
Virus Infection

Fields, H. A.; Khudyakov, Y.; Favorov, M.
Patent Issued: 29 August 95
Patent No. 5,445,932 (Ref # E-069-92/0)

    Reagents and methods for the detection of a marker which is 
associated with severe forms of hepatitis delta have been developed. 
This invention detects the presence of anti-HDAg' antibodies in a 
biological sample. It also describes a vaccine comprised of 
immunogenically active HDAg' polypeptides in a pharmaceutically 
acceptable carrier. (Portfolio: Hepatitis Delta, Vaccine, Diagnosis.)

DNA Sequence Encoding a Cynomolgus Monkey Hepatitis A Virus Capsid 
Protein

Nainan, O. V.; Margolis, H. S.; Robertson, B. H.; Brinton, M. A.; 
Ebert, J. W.
Patent Issued: 4 July 95
Patent No. 5,430,135 (Ref # E-089-91/1)

    This invention relates to substantially pure preparations of the 
cynomolgus monkey hepatitis A viral isolates CY-145 and CY-55/JM-55, 
which may be used in the prevention of hepatitis A in animals. This 
invention provides a virus that may be adapted in a cell-line suitable 
for human vaccine development or may be cloned into an expression 
vector in which the cDNA coding for the capsid region of the virus may 
provide a virus-like antigen which could substitute for the whole 
virus. (Portfolio: Hepatitis A, Diagnosis, Vaccine.)

Nucleic Acid Probes and Methods for Detecting Candida DNA Cells in 
Blood

Lot, T. J.; Morrison, C. J.; Reiss, E.; Lasker, B.; Zakroff, S.
Patent Issued: 20 June 95
Patent No. 5,426,027 (Ref # E-118-93/0)

    An isolated double-stranded nucleic acid sequence specific for 
Candida albicans, as well as ITS2 sequences for C. Parapsilosis, C. 
Tropoicalis, C. Glabrata and C. Krusei, is provided. This invention 
also contemplates an isolated nucleic acid that specifically hybridizes 
with, or selectively amplifies, a nucleic acid of C. albicans. These 
sequences may be used in a rapid method of diagnosing systemic 
candidiasis in patients by detecting C. albicans in blood samples with 
concentration as low as 10 cells per ml. (Portfolio: Nucleic Acid 
Sequencing, Candida, Diagnostics.)

Ear Based Hearing Protector/Communication System

Franks, J. R.; Sizemore, C. W.; Dunn,
    D. E.
Patent Issued: 20 June 95
Patent No. 5,426,719 (Ref # E-154-91/0)

    A combination hearing protector and communication device which may 
be incorporated into earmuffs/earplugs has been developed. The system 
allows dual channels and does not compromise the noise-reducing 
characteristics of normal earmuffs or earplugs. The system incorporates 
an independent transmission channel with the wearer having the 
possibility of receiving the same channel as other wearers. (Portfolio: 
Ear Protection, Communication, Hearing Safety.)

PsaA

Russell, H.; Sampson, J.; O'Connor, S.
Patent Issued: 6 June 95
Patent No. 5,422,427 (Ref # E-157-91/0)

    The patent claims a DNA sequence encoding a pneumonacoccal surface 
adhesin A protein (PsaA), formerly designated as pneumococcal fimbrial 
protein. This sequence may be utilized to relates to produce a PsaA 
polypeptide. The sequence may also be utilized to design diagnostics 
for measuring the amount of PsaA contained in a sample. Vaccines which 
may be efficacious in adults or children may be developed using the 
sequence or polypetides. (Portfolio: Vaccine, Diagnosis, Pneumococal 
Surface Adhesin A Protein.)

Streptococcus Pneumoniae 37-KDa Surface Adhesin A Protein

Sampson, J.; Russell, H.; Tharpe, J.; Ades, E.; Carlone, G.
Filed 17 September 1996
Serial No.08/715,131 (Ref # E-157-91/4)

    This invention provides the isolated nucleic acid encoding the 37-
kDa protein of Streptococcus pneumoniae designated pneumococcal surface 
adhesin A protein (PsaA), formerly designated as pneumococcal fimbrial 
protein. This invention relates to purified polypetides encoded by the 
sequence and a method of measuring the amount of PsaA contained in a 
sample. This invention also includes a vaccine that may be efficacious 
in adults or children. (Portfolio: Vaccine, Diagnosis, Pneumococal 
Surface Adhesin A Protein.)

Use of Human Immortalized Endothelial Cells to Isolate and Propagate 
Ehrlichia chaffeensis and Ehrlichia canis

Dawson, J. E.
Patent Issued: 28 March 95
Patent No. 5,401,656 (Ref # E-155-91/0)

    This invention provides a purified immortalized human endothelial 
cell infected with Ehrlichia Chaffeensis or Ehrlichia canis. The 
invention provides a method for simultaneously screening a human 
subject for E. Chaffeensis or Rickettsia rickettsii. Also provided is a 
method of culturing E. chaffeensis and E. Canis. (Portfolio: Diagnosis, 
Ehrlichiosis, Cell Culture.)

Immunoreactive HTLV-I/II and POL Peptides

Lal, R. B.
Patent Issued 3 January 1995
Patent No. 5,378,805 (Ref # E-172-90/0)

    This invention relates to a peptide having specific 
immunoreactivity to antibodies to HTLV-I, HTLV-II derived from the 
structural gene products from groups consisting of Env-1, Env-2,

[[Page 28048]]

Env-5, Gag-1a, and Pol-3. This invention is further directed to an 
immunoassay method for the detection of antibodies, a peptide 
composition containing these peptides, and a vaccine. (Portfolio: HTLV, 
Vaccine, Diagnostics.)

Methods and Compositions for Diagnosing HTLV-1 Associated Myelopathy 
and Adult T-Cell Leukemia

Rudolph, D. L.; Lal, R. B.
Patent Issued 30 May 1995
Patent No. 5,420,244 (Ref # E-206-93/0)

    This invention provides antigenic peptides derived from 
immunodominant epitopes of the HTLV-I tax or rex proteins that are 
immunoreactive with antibodies associated with disease in HTLV-I 
infected subjects. This invention provides peptides corresponding to 
the immunodominant epitopes of the rex regulatory protein of HTLV-I. 
This invention provides methods for diagnosing HTLV-I associated 
myelopathy. This invention also provides methods for diagnosing adult 
T-cell leukemia. (Portfolio: HTLV-I, HIV, Antibodies, HAM [HTLV-I 
Associated Myelopathy], T-cell Leukemia, Diagnosis.)

Isolation of Diagnostic Glycoproteins to Taenia Solium, Immunoblot-
assay and Method for the Detection of Human Cysticercosis

Tsang, V. C. W.; Brand, J.; Boyer, A.; Wilson, M.; Schantz, P.; 
Maddison, S.
Patent Issued 11 October 94
Patent No. 5,354,660 (Ref # E-185-88/1)

    This invention is a method and a kit for diagnosing active human 
neurocysticercosis utilizing an immunoblot assay. This method allows 
diagnosis of neurocysticercosis by the detection antigens of larval 
origin. This invention improves on the specificity and sensitivity of 
the disc method achieving 98% sensitivity and 100% specificity. This 
allows the detection of antibodies in the serum or cerebrospinal fluid. 
(Portfolio: Larval Detection, Taenia solium, Neurocysticercosis, 
Diagnosis.)

Exchangeable Template Reaction

Khudyakov, Y.; Fields, H.
Patent Issued: 2 April 96
Patent No. 5,503,995 (Ref # E-184-91/1)

    This invention provides a method of making synthetic DNA of any 
desired sequence. This invention can be used to make an array of DNA 
having specific substitution in a known sequence which are expressed 
and screened for improved function. This invention provides a method 
for the synthesis of DNA based on a cyclic mechanism of combining 
deoxyoligonucleotides. Also included is a kit comprising a series of 
unique synthesized single-stranded deoxypolynucleotides which can be 
enzymatically treated to form a unique 3' single-stranded protrusion 
for selective cyclic hybridization with another unique single-stranded 
deoxypolynucleotide of the series.(Portfolio: DNA, DNA Synthesis.)

Sequences of the Hemagglutinins of Recent Strains of Influenza Type B 
virus

Rota, P. A.; Hemphill, M. L.
Patent Issued: 20 December 94
Patent No. 5,374,717 (Ref # E-224-92/0)

    This invention provides sequence analyses for recent strains of 
Influenza Type B virus. This invention also provides a method for 
vaccinating a mammal against influenza type B. This invention also 
provides a method of detection and diagnosis of an infection with 
influenza type B virus. (Portfolio: Virus, Influenza Type B, Vaccine.)

Method for Detecting Isocyanates

Streicher, R. P.
Patent Issued 11 October 94
Patent No. 5,354,689 (Ref # E-215-92/0)

    This invention provides a method for detecting the presence of 
isocyanate in a sample. Also, the invention provides a method of 
quantifying the total isocyanate presence by quantifying the reaction 
product. This invention is particularly well-suited to the detection of 
isocyanates in air. (Portfolio: Isocyanate, Detection.)

Portable Spirometer With Improved Accuracy

Hankinson, J. L.; Viola, J. C.; Ebeling, T. H.
Patent Issued 8 October 96
Patent No. 5,562,101 (Ref # E-030-92/1)

    This invention is a spirometric measurement device with an 
arrangement for computation of a dynamic correction factor to 
compensate for temperature-related changes. This invention improves the 
accuracy by increasing the analog-to-digital conversion resolution, by 
modifying the dithering process, and by compensating for the inherent 
transducer temperature drift. This invention provides for a multi-
functional, downloadable, flexible spirometric device, that requires no 
disassembly with improved quality control. (Portfolio: Spirometric, 
Lung Capacity, Respiratory Function.)

    Dated: May 16, 1997.
Joseph R. Carter,
Acting Associate Director for Management and Operations, Centers for 
Disease Control and Prevention (CDC).
[FR Doc. 97-13427 Filed 5-21-97; 8:45 am]
BILLING CODE 4163-18-P